Sleep apnea, a condition characterized by repeated interruptions in breathing during sleep, may have broader implications beyond immediate daytime fatigue, including potential contributions to cognitive decline and symptoms resembling aging, according to recent research. Experts highlight that the condition can lead to repeated "mini awakenings" throughout the night, which disrupt restorative sleep and may affect memory and thinking.

One challenge in diagnosing sleep apnea is that its cognitive symptoms—such as brain fog, forgetfulness, slower reaction times, and difficulty making decisions—are often nonspecific and may be mistaken for normal aging. This overlap can lead to underdiagnosis, particularly among older adults who live alone and lack a bed partner who might observe key signs like loud snoring and breathing pauses. Studies have found marital status to be a significant factor in whether individuals receive a diagnosis, suggesting the importance of observations by others in recognizing the disorder.

Researchers have also pointed to longer-term risks associated with untreated sleep apnea. Repeated episodes of low oxygen levels during sleep can raise blood pressure and trigger changes in the brain. Over time, these oxygen dips may have cumulative effects, potentially increasing the risk for cognitive decline and conditions like Alzheimer’s disease. Additionally, interrupted sleep may impair the brain’s ability to clear toxic proteins linked to neurodegenerative diseases. A 2026 randomized controlled trial demonstrated that a normal night’s sleep improved the clearance of such biomarkers compared to sleep deprivation.

Treatment options, particularly continuous positive airway pressure (CPAP) therapy, which keeps the airway open during sleep, show promise in slowing cognitive decline for people with sleep apnea. A recent study co-authored by Christopher Kaufman, an assistant professor at the University of Florida College of Medicine, found that patients using CPAP experienced slower cognitive deterioration than those who did not. Other treatments include oral devices that adjust jaw or tongue position and the GLP-1 medication Zepbound, which is approved for moderate to severe obstructive sleep apnea in adults with obesity.

Diagnosis typically requires an overnight sleep study, during which heart rate, lung function, breathing patterns, and oxygen levels are monitored. While symptoms such as insomnia, fatigue, and morning headaches may raise suspicion, they alone are insufficient for diagnosis due to their nonspecific nature. Physicians may also consider sleep apnea’s role when patients face challenges in controlling blood pressure or experience worsening cardiovascular health.

Researchers emphasize the need for further study to determine if aggressively treating sleep apnea and other sleep problems can prevent or reduce cognitive decline and dementia risk. “We have a lot of good evidence showing that sleep is important for cognitive health,” said one expert, noting the importance of understanding how to leverage sleep interventions to improve long-term brain health.